Figure 2.
Survival analysis of ARRDC3 in ovarian cancer by OS, PFS, PPS as well as stratified analysis by serous carcinoma and endometrioid carcinoma types. (A–C) Survival analysis of ARRDC3 in ovarian cancer by as well as stratified analysis by serous carcinoma and endometrioid carcinoma types, respectively; (D–F) survival analysis of ARRDC3 in ovarian cancer by PFS well as stratified analysis by serous carcinoma and endometrioid carcinoma types, respectively; (G and H) survival analysis of ARRDC3 in ovarian cancer by PPS well as stratified analysis by serous carcinoma type, respectively.
